Skip to main content

Drug Interactions between argatroban and Sandostatin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

No interactions were found between argatroban and Sandostatin. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

argatroban

A total of 155 drugs are known to interact with argatroban.

Sandostatin

A total of 155 drugs are known to interact with Sandostatin.

Drug and food interactions

Moderate

octreotide food

Applies to: Sandostatin (octreotide)

MONITOR: Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications. Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat. Clinical data are limited, however. In case reports, octreotide has been reported to reduce the relative bioavailability of cyclosporine. Transplant rejection and significant reductions in cyclosporine levels, sometimes to undetectable levels, have been reported in association with the interaction. Vitamin K absorption was not affected when concomitantly administered with lanreotide according to the manufacturer.

MANAGEMENT: Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs. Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.

References

  1. Landgraf R, Landgraf-Leurs MM, Nusser J, et al. "Effect of somatostatin analogue (SMS201-995) on cyclosporine levels." Transplantation 44 (1987): 724-5
  2. Ho PJ, Boyajy LD, Greenstein E, Barkan AL "Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly." Dig Dis Sci 38 (1993): 309-15
  3. Katz MD, Erstad BL "Octreotide, a new somatostatin analogue." Clin Pharm 8 (1989): 255-73
  4. "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation PROD (2001):
  5. "Product Information. Somatuline Depot (lanreotide)." Ipsen Inc (2007):
View all 5 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer